Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15566859 | 0.88 | GPR6 (0.62) | GPR6CYP2D6 | |
| SCHEMBL15566411 | 0.83 | GPR6 (0.60) | GPR6 | |
| Hydrochloric Acid SCHEMBL15566557 | 0.82 | GPR6 (0.59) | GPR6 | |
| Hydrochloric Acid SCHEMBL15566736 | 0.82 | GPR6 (0.59) | GPR6 | |
| SCHEMBL15567016 | 0.80 | GPR6 (0.63) | GPR6 | |
| SCHEMBL15566253 | 0.76 | GPR6 (0.66) | GPR6 | |
| Trifluoroacetic Acid SCHEMBL15566616 | 0.76 | GPR6 (0.64) | GPR6 | |
| SCHEMBL15567217 | 0.74 | GPR6 (0.84) | GPR6CYP2D6 | |
| SCHEMBL15566347 | 0.74 | GPR6 (0.84) | GPR6CYP2D6 | |
| SCHEMBL4317202 | 0.74 | PDE4A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR6 1/4885CYP2D6 137/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR6 1/4885CYP2D6 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.